RayKnowChina Research Map
Shortlist

Cancer

Lung cancer in Shanghai

上海 肺癌

All diseases in Shanghai

22 hospitals in Shanghai

Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 414 papers led
  2. 394 papers led
  3. 243 papers led
  4. 186 papers led
  5. 88 papers led
  6. 68 papers led
  7. 62 papers led
    No open trial led
  8. 61 papers led
    No open trial led
  9. 50 papers led
  10. 49 papers led
  11. 44 papers led
    No open trial led
  12. 43 papers led
    No open trial led
  13. 42 papers led
    No open trial led
  14. 40 papers led
    No open trial led
  15. 33 papers led
    No open trial led
  16. 32 papers led
    No open trial led
  17. 30 papers led
    No open trial led
  18. 28 papers led
    No open trial led
  19. 20 papers led
  20. 6 papers led
  21. 1 paper led
    No open trial led
  22. 0 papers led
    No open trial led

Lung cancer in every city Shanghai on the disease page, with the national map

344

open trials on lung cancer with a hospital in Shanghai

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 147 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    Phase
    Phase 2/Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07063745

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen

  2. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  4. Recruiting
    A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07227025

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai

  5. Recruiting
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227298

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan

  6. Recruiting
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227597

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou

  7. Recruiting
    Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07231445

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  8. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07253142

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou

  9. Recruiting
    A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07269782

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  10. Recruiting
    Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07288177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou

  11. Recruiting
    A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07308106

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  12. Recruiting
    A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07309276

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  13. Recruiting
    Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07323056

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  14. Recruiting
    A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07325136

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai East Hospital, Tongji UniversityShanghai

  15. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  16. Recruiting
    A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361510

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou

  17. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  18. Recruiting
    Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07398937

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  19. Recruiting
    IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07408635

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  20. Recruiting
    Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07410975

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  21. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  22. Recruiting
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07416695

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  23. Recruiting
    MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07431827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan

  24. Recruiting
    A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07434518

    Age 18 years to 100 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  25. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  26. Recruiting
    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07476287

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou

  27. Recruiting
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07489066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  28. Recruiting
    A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07502300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  29. Recruiting
    Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07515027

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  30. Recruiting
    JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07518160

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  31. Recruiting
    Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07528066

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  32. Recruiting
    RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07541521

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  33. Recruiting
    Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07549061

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  34. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  35. Recruiting
    Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07554846

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  36. Recruiting
    A Phase II Study of GC101 in NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560111

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  37. Recruiting
    A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07562581

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  38. Recruiting
    Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07564557

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  39. Recruiting
    Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07565532

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  40. Recruiting
    A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07586202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin

  41. Recruiting
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07623356

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  42. Recruiting
    Association Between Screening Behaviors and Lung Cancer Spectrum
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07626177

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  43. Recruiting
    A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
    Phase
    Phase 2/Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07642024

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  44. Recruiting
    A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07654400

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  45. Recruiting
    A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07668752

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  46. Recruiting
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07672223

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  47. Recruiting
    Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07681245

    Age 18 years to 90 years (registered criteria)

    Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  48. Recruiting
    SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07697586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  49. Recruiting
    DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07707895

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesNanning, Shanghai

  50. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  51. Recruiting
    Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
    Phase
    Phase 4
    Started
    2026-06
    Posted
    Registry
    NCT07754812

    Age 70 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai

  52. Recruiting
    Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07778316

    Age 18 years to 99 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  53. Recruiting
    A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07802821

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  54. Recruiting
    Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07806604

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  55. Recruiting
    Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07807696

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  56. Recruiting
    A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
    Phase
    Phase 1
    Started
    2026-09
    Posted
    Registry
    NCT07830342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  57. Recruiting
    A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07843940

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Harbin, Shanghai

  58. Recruiting
    Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07863999

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 4 listed hospitals as study sitesShanghai

  59. Recruiting
    Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07874581

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  60. Recruiting
    Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880353

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  61. Recruiting
    The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT05798845

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  62. Recruiting
    Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06687408

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Shanghai

  63. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  64. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  65. Recruiting
    The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06738160

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  66. Recruiting
    A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06754930

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  67. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  68. Recruiting
    Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06758700

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  69. Recruiting
    Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06772623

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou

  70. Recruiting
    ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06775743

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  71. Recruiting
    Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06780098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou

  72. Recruiting
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06780137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai

  73. Recruiting
    A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06792552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang

  74. Recruiting
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06793215

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan

  75. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  76. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

  77. Recruiting
    Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06818149

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  78. Recruiting
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06839105

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan

  79. Recruiting
    DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06846762

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  80. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  81. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  82. Recruiting
    A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT06868485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan

  83. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  84. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  85. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  86. Recruiting
    A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06901817

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  87. Recruiting
    Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06903117

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  88. Recruiting
    Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06903377

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  89. Recruiting
    Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06927986

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  90. Recruiting
    Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06928389

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  91. Recruiting
    Sleep Disorders and Tumor Immune Microenvironment
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06941948

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  92. Recruiting
    Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06943235

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  93. Recruiting
    A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06954246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  94. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06955988

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  95. Recruiting
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06968221

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  96. Recruiting
    Transbronchial MWA for Pulmonary Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06969014

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  97. Recruiting
    Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06987734

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  98. Recruiting
    A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07003321

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  99. Recruiting
    Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07003490

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  100. Recruiting
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07005102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan

  101. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  102. Recruiting
    A Study of SKB518 in Patients With Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07019675

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou

  103. Recruiting
    A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07056556

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  104. Recruiting
    A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07058519

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  105. Recruiting
    Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07063329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  106. Recruiting
    DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07070440

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  107. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  108. Recruiting
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07079475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin

  109. Recruiting
    A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07091305

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  110. Recruiting
    Perioperative Immunotherapy for Resectable Limited-Stage SCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07109401

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  111. Recruiting
    ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07109531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  112. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  113. Recruiting
    Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07117890

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  114. Recruiting
    Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07134660

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  115. Recruiting
    Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07135856

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  116. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07144280

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  117. Recruiting
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07154706

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou

  118. Recruiting
    A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07155174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Nanchang, Shanghai, Wuhan, Zhengzhou

  119. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07155187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Urumqi

  120. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07164170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou

  121. Recruiting
    HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07169552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  122. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  123. Recruiting
    A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07171606

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  124. Recruiting
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07174908

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  125. Recruiting
    A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07181473

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai, Wuhan, Zhengzhou

  126. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  127. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  128. Recruiting
    Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07189455

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  129. Recruiting
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07190248

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  130. Recruiting
    Study on the Mechanism of Acquired Resistance of Entrectinib
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07199959

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  131. Recruiting
    A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206498

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  132. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  133. Recruiting
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07218146

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  134. Recruiting
    Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07226999

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  135. Recruiting
    A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07229599

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  136. Recruiting
    Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07232433

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  137. Recruiting
    A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07232849

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  138. Recruiting
    Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07243873

    Age 18 years to 85 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Zunyi

  139. Recruiting
    A Study of Ivonescimab in First-Line ES-SCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07245446

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an

  140. Recruiting
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07252739

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Nanchang, Nanjing, Shanghai

  141. Recruiting
    Exploratory Trial of Navigational Bronchoscopy-Guided Cryoablation in Lung Cancer Treatment
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07301411

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  142. Recruiting
    A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07361237

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai East Hospital, Tongji UniversityShanghai

  143. Recruiting
    A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07362459

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  144. Recruiting
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07376707

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  145. Recruiting
    Effectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07662733

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  146. Recruiting
    Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07742332

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  147. Recruiting
    Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07801430

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  148. Recruiting
    Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT05613452

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  149. Recruiting
    Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06127303

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai

  150. Recruiting
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06179069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou

  151. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  152. Recruiting
    WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
    Phase
    Phase 1/Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06243003

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  153. Recruiting
    Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06256237

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  154. Recruiting
    Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06258642

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  155. Recruiting
    Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06269211

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 1 listed hospital as study siteGuangzhou, Shanghai

  156. Recruiting
    Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06283719

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  157. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  158. Recruiting
    A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06306456

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Hefei, Nanjing, Shanghai, Taizhou, Zhengzhou

  159. Recruiting
    Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06311981

    Age 75 years to Not stated (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  160. Recruiting
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06312137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou

  161. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  162. Recruiting
    A Study of GC203 TIL in Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06375187

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  163. Recruiting
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06403735

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai

  164. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  165. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  166. Recruiting
    A Study of FZ-AD005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06424665

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Hangzhou, Shanghai

  167. Recruiting
    A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06430437

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  168. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06437509

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  169. Recruiting
    Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06437977

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  170. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  171. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  172. Recruiting
    A Phase Ib Study of GC101 in NSCLC
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06473961

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  173. Recruiting
    Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06483295

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  174. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  175. Recruiting
    Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06501391

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  176. Recruiting
    Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06503744

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  177. Recruiting
    A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06505824

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  178. Recruiting
    Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06518655

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan

  179. Recruiting
    Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06528847

    Age 18 years to 74 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  180. Recruiting
    Primary Tumor Resection for M1a Stage Lung Cancer
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06547710

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  181. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  182. Recruiting
    Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
    Phase
    Phase 4
    Started
    2024-05
    Posted
    Registry
    NCT06561620

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  183. Recruiting
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06564324

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  184. Recruiting
    Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06567015

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

  185. Recruiting
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06572540

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou

  186. Recruiting
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06598306

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  187. Recruiting
    A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06612840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  188. Recruiting
    The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06623487

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  189. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  190. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  191. Recruiting
    Segmentectomy for Solid-dominant Lung Cancer
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06634966

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  192. Recruiting
    Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
    Phase
    N/A
    Started
    2024-05
    Posted
    Registry
    NCT06634979

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  193. Recruiting
    High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06652048

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  194. Recruiting
    Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06659042

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  195. Recruiting
    Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06663306

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  196. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06668103

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan

  197. Recruiting
    Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06684418

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  198. Recruiting
    Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06698965

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  199. Recruiting
    Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06739031

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  200. Recruiting
    Lymph Node Pathologic Grading Strategy
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06745830

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  201. Recruiting
    Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06749860

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  202. Recruiting
    An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06749886

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  203. Recruiting
    Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06755684

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  204. Recruiting
    68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06756217

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  205. Recruiting
    A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06780826

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  206. Recruiting
    Trop2-targeted immunoPET Imaging of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Posted
    Registry
    NCT06851663

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  207. Recruiting
    Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT07026110

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  208. Recruiting
    Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT07399210

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  209. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  210. Recruiting
    An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT07444281

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  211. Recruiting
    Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
    Phase
    Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05717803

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  212. Recruiting
    Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05766800

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  213. Recruiting
    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05786924

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou

  214. Recruiting
    A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05789082

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Harbin, Shanghai

  215. Recruiting
    Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-01
    Posted
    Registry
    NCT05800223

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  216. Recruiting
    Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05857800

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  217. Recruiting
    DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05882058

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Hangzhou, Jinan, Nanchang, Shanghai

  218. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  219. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  220. Recruiting
    Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT05965024

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  221. Recruiting
    Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05965557

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  222. Recruiting
    Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05987826

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  223. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  224. Recruiting
    Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT06031181

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  225. Recruiting
    Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT06041776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  226. Recruiting
    Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT06052098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  227. Recruiting
    SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT06080776

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  228. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  229. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  230. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  231. Recruiting
    A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06147570

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  232. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  233. Recruiting
    Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06205927

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  234. Recruiting
    Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06216782

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  235. Recruiting
    DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT06276283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  236. Recruiting
    Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT06343064

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  237. Recruiting
    Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06358222

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  238. Recruiting
    Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT06534489

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  239. Recruiting
    Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06730503

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  240. Recruiting
    Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT07070011

    Age 45 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  241. Recruiting
    Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT07328945

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  242. Recruiting
    ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
    Phase
    N/A
    Started
    2022-02
    Posted
    Registry
    NCT03786003

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  243. Recruiting
    SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
    Phase
    N/A
    Started
    2022-02
    Posted
    Registry
    NCT04527419

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  244. Recruiting
    Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT04728724

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  245. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  246. Recruiting
    Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
    Phase
    N/A
    Started
    2022-10
    Posted
    Registry
    NCT04973293

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  247. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  248. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  249. Recruiting
    First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05271916

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  250. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  251. Recruiting
    Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
    Phase
    Phase 3
    Started
    2022-06
    Posted
    Registry
    NCT05382728

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  252. Recruiting
    A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05482568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  253. Recruiting
    A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
    Phase
    Phase 3
    Started
    2022-12
    Posted
    Registry
    NCT05487391

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  254. Recruiting
    China Lung Cancer Screening (CLUS) Study Version 3.0
    Phase
    N/A
    Started
    2022-01
    Posted
    Registry
    NCT05494021

    Age 45 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  255. Recruiting
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05498428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai

  256. Recruiting
    Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-02
    Posted
    Registry
    NCT05503667

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  257. Recruiting
    Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05536505

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan

  258. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  259. Recruiting
    Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT07632365

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  260. Recruiting
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04886804

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

  261. Recruiting
    A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
    Phase
    Phase 2
    Started
    2021-01
    Posted
    Registry
    NCT04905056

    Age 18 years to 85 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  262. Recruiting
    A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
    Phase
    Phase 1
    Started
    2021-08
    Posted
    Registry
    NCT04913285

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Linyi, Shanghai

  263. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  264. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai

  265. Recruiting
    Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT05053802

    Age 18 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesShanghai

  266. Recruiting
    First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 1/Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05099172

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou

  267. Recruiting
    Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
    Phase
    N/A
    Started
    2021-01
    Posted
    Registry
    NCT05552846

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  268. Recruiting
    Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT06369181

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  269. Recruiting
    A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
    Phase
    Phase 3
    Started
    2020-07
    Posted
    Registry
    NCT04316364

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou

  270. Recruiting
    PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04539977

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  271. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  272. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  273. Recruiting
    Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
    Phase
    N/A
    Started
    2019-10
    Posted
    Registry
    NCT04937283

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 8 listed hospitals as study sitesHangzhou, Hefei, Nantong, Ningbo, Shanghai, Xuzhou

  274. Recruiting
    Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT05701787

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  275. Recruiting
    Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
    Phase
    Not given
    Started
    2019-08
    Posted
    Registry
    NCT05838053

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  276. Recruiting
    Study of High Efficient Killing Cell Therapy for Advanced NSCLC
    Phase
    Phase 1
    Started
    2017-09
    Posted
    Registry
    NCT03193567

    Age 18 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  277. Recruiting
    Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
    Phase
    Phase 2
    Started
    2017-09
    Posted
    Registry
    NCT03351842

    Age 19 years to 70 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  278. Recruiting
    Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
    Phase
    Phase 2
    Started
    2017-08
    Posted
    Registry
    NCT03392233

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  279. Recruiting
    Integrative Analysis of Large-cell Lung Cancer
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT02917369

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  280. Recruiting
    Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2016-07
    Posted
    Registry
    NCT04977791

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  281. Recruiting
    Molecular Analysis and Treatment Options of SCLC
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT05945745

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  282. Recruiting
    Association of Psychological Distress in Patients With Lung Cancer
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT06218901

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  283. Recruiting
    A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2008-01
    Posted
    Registry
    NCT02889666

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  284. Not yet recruiting
    A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
    Phase
    Phase 1/Phase 2
    Started
    2027-12
    Posted
    Registry
    NCT05745740

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  285. Not yet recruiting
    A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07014878

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  286. Not yet recruiting
    Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
    Phase
    Phase 4
    Started
    2026-01
    Posted
    Registry
    NCT07358520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xuzhou

  287. Not yet recruiting
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07360132

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  288. Not yet recruiting
    A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07375979

    Age 40 years to 74 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesChangchun, Kunming, Shanghai, Shenyang, Zhengzhou

  289. Not yet recruiting
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07383116

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  290. Not yet recruiting
    A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07414927

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  291. Not yet recruiting
    A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
    Phase
    Phase 4
    Started
    2026-04
    Posted
    Registry
    NCT07469488

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  292. Not yet recruiting
    Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07493980

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  293. Not yet recruiting
    Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07517640

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  294. Not yet recruiting
    A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07538973

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesQingdao, Shanghai

  295. Not yet recruiting
    A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07550842

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou

  296. Not yet recruiting
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07558200

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  297. Not yet recruiting
    A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07583771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  298. Not yet recruiting
    Application of Electromagnetic Navigation System in Pulmonary Nodule Localization
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07595120

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  299. Not yet recruiting
    Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07698990

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  300. Not yet recruiting
    HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07699757

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  301. Not yet recruiting
    The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07704645

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  302. Not yet recruiting
    A Phase 2 Study of ABSK043 Combined With Osimertinib
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07710612

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan

  303. Not yet recruiting
    JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07714304

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai

  304. Not yet recruiting
    Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07745790

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  305. Not yet recruiting
    The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07780578

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  306. Not yet recruiting
    5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
    Phase
    N/A
    Started
    2026-11
    Posted
    Registry
    NCT07830095

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  307. Not yet recruiting
    A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07831863

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  308. Not yet recruiting
    Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07874282

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  309. Not yet recruiting
    Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07889297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  310. Not yet recruiting
    Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07890636

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  311. Not yet recruiting
    A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-12
    Posted
    Registry
    NCT07896005

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  312. Not yet recruiting
    ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07897188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  313. Not yet recruiting
    Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07912268

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Fuzhou, Harbin, Nanchang, Shanghai

  314. Not yet recruiting
    Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06688656

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  315. Not yet recruiting
    Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06837948

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  316. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  317. Not yet recruiting
    Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07064876

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  318. Not yet recruiting
    A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07086326

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an

  319. Not yet recruiting
    Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07097948

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  320. Not yet recruiting
    A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07101627

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 1 listed hospital as study siteNanjing, Shanghai

  321. Not yet recruiting
    Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07135297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou

  322. Not yet recruiting
    Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07156604

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  323. Not yet recruiting
    Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07169903

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  324. Not yet recruiting
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07199010

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  325. Not yet recruiting
    The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07277088

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  326. Not yet recruiting
    Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06332950

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  327. Not yet recruiting
    Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06453889

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  328. Not yet recruiting
    Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06456138

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  329. Not yet recruiting
    Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06580665

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Wenzhou, Wuhan

  330. Not yet recruiting
    A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06585644

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  331. Not yet recruiting
    TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06619886

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  332. Not yet recruiting
    Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06620822

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  333. Not yet recruiting
    A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06690671

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  334. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  335. Not yet recruiting
    The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-08
    Posted
    Registry
    NCT05496166

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  336. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  337. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

  338. Not yet recruiting
    Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
    Phase
    Phase 1
    Started
    2023-09
    Posted
    Registry
    NCT06015568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBengbu, Changsha, Shanghai

  339. Not yet recruiting
    Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06102161

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  340. Not yet recruiting
    Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06109402

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  341. Enrolling by invitation
    Perioperative Treatment Outcomes of Early NSCLC
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06610240

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  342. Enrolling by invitation
    Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06962449

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  343. Enrolling by invitation
    The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT07060625

    Age 18 years to 85 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  344. Enrolling by invitation
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04762459

    Age 18 years to 130 years (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Shanghai

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Shanghai, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Cancer Hospital, Fudan Universitynonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Changhai Hospital海军军医大学第一附属医院(长海医院)2221 open19315 open201 open8812 open101 open7none2none110nonenonenonenonenone9nonenonenonenonenonenone01 opennonenonenonenone417none1none2nonenonenonenonenonenone1none1nonenonenone1none001none0nonenonenonenone
Changzheng Hospital海军军医大学第二附属医院(长征医院)none3151 open171 open4041 opennone10nonenone516402262 opennonenonenone6nonenonenone1nonenonenonenonenonenonenone5none81nonenone2none0nonenonenonenone1none5nonenone21nonenonenonenonenone1nonenonenonenone
Child Health Hospitalnonenonenonenonenonenone26nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children Hospital, Fudan Universitynonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Fudan University复旦大学附属儿科医院nonenonenonenonenonenonenone115004none111none0none0501 opennone1nonenonenonenone12none213 open5372 open310nonenonenonenone311 open021021none1none1042none0none10none
Dahua Hospitalnonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
East Hospital上海市东方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)nonenone2144 open6none7nonenonenonenonenone41nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenone
Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院324 opennonenonenonenonenonenonenonenone63 open0nonenone51 opennonenonenonenonenone161 opennonenonenonenonenonenonenonenonenonenonenonenone17nonenone0nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenone
Fengxian District Central Hospital上海市奉贤区中心医院none3nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院nonenonenonenonenone2nonenonenonenone11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Naval Medical Universitynonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Rehabilitation Hospital, Tongji University上海市第一康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院381 open328 open542 open8817 open24331 open21211 open39090 open15nonenone360none4none0nonenone3318 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Gongli Hospital上海市浦东新区公利医院nonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gynecology Hospital, Fudan University复旦大学附属妇产科医院nonenonenonenonenonenone17nonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Huadong Hospital, Fudan University复旦大学附属华东医院none11 opennone41 open42111 opennonenonenonenonenone0nonenonenonenonenonenone06nonenonenonenonenonenonenonenone2nonenone14nonenonenonenonenone0none0nonenonenonenone24none1nonenonenonenonenone1nonenonenonenonenonenonenonenone
Huashan Hospital复旦大学附属华山医院none12621 open226 open62191 open261 open1226 opennonenone420105nonenonenone351 opennone1nonenonenone231 open0314 open17nonenone53none1nonenone7none1011none111none6nonenonenone00nonenone21nonenonenonenonenone
Infant Hospital上海市第一妇婴保健院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone30nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiading District Anting Hospital上海市嘉定区安亭医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiahui International Hospital上海嘉会国际医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jing'an District Centre Hospital上海市静安区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jinshan Hospital, Fudan University复旦大学附属金山医院nonenonenonenonenonenonenonenonenonenonenone5none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone
Longhua Hospital上海中医药大学附属龙华医院none7111344none36nonenonenone14none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone51 opennone2nonenonenone1nonenonenonenonenonenonenonenone1nonenonenone20nonenonenonenone1nonenonenonenone
Minhang Hospital上海市闵行区中心医院nonenonenone9nonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Putuo Hospital上海市普陀区中心医院nonenonenonenonenonenonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Renji Hospital上海交通大学医学院附属仁济医院22 open81 open1045 open655 open883 open1037 open7620 open251 open3113102none242 opennonenone3232 opennonenone1nonenone111 open231 opennonenone31110020none0none3none1none02none6nonenonenone171 open5nonenonenone2nonenonenonenonenone
Ruijin Hospital上海交通大学医学院附属瑞金医院none221 open353 open9613 open6811 open11418 open11518 open14nonenonenone131 open22022114 opennone29755 open05none0nonenonenonenone2nonenone594 open211nonenone02203nonenonenone142 opennonenonenone0nonenonenonenonenone2nonenonenonenone
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Chest Hospital上海市胸科医院none4012 opennonenone41445 opennonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone114nonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Children's Hospital上海市儿童医院nonenonenonenonenonenonenonenonenonenonenone1none61none1none1none40nonenonenonenonenonenonenonenone1none102nonenonenonenonenonenonenonenonenone20000nonenonenonenone2nonenonenonenonenonenonenonenone
Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心nonenonenonenonenonenonenonenone171 opennonenone0none110none81 open5none110nonenonenone2nonenonenonenonenonenonenone971 open2nonenonenonenonenonenone00002 opennonenone30nonenonenonenone221nonenonenonenonenonenone
Shanghai East Hospital, Tongji University同济大学附属东方医院1133637502 open125013none01222113nonenonenone7nonenonenonenone1nonenonenonenonenonenone201 open11nonenonenonenone4none11 opennonenonenonenonenonenone1nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Eighth People Hospital上海市第八人民医院nonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Electric Power Hospital上海电力医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fengxian District Central Hospitalnonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院nonenonenonenonenonenonenonenone1nonenone1nonenonenone31 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai General Hospital上海市第一人民医院53361 open271 open494 open357 open6213none152420none200none118 opennone0nonenonenonenonenonenonenonenonenone254none11none1none1nonenonenonenonenonenone0nonenonenonenone0nonenonenonenonenone2nonenonenone
Shanghai Jiading Central Hospital上海市嘉定区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Mengchao Cancer Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Mental Health Center上海市精神卫生中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院nonenonenonenone28nonenonenonenonenonenone2none10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone11nonenonenonenonenonenonenonenonenone
Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院54nonenone3311279none29none1512nonenonenonenonenone221 opennone1nonenone1nonenonenonenonenonenone1502none0none4nonenone0nonenone11none0nonenone10nonenone01nonenone1nonenonenone
Shanghai Proton and Heavy Ion Center上海市质子重离子医院0none2none63 open01 open13 open2nonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong Hospital上海市浦东医院nonenonenonenonenone2106none0none0nonenonenone10nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院nonenonenonenonenonenonenonenonenonenonenone0none00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pulmonary Hospital上海市肺科医院none5nonenone39443 opennonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone71 opennonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Putuo District Liqun Hospital上海市普陀区利群医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Sixth People's Hospital上海市第六人民医院3027214315438nonenone0350411nonenonenonenonenonenonenonenonenone2nonenonenonenonenone112nonenonenonenone2none4nonenonenone0none00nonenone711nonenonenonenone0nonenonenonenone
Shanghai Songjiang District Central Hospital上海市松江区中心医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Stomatological Hospital上海市口腔医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tenth People's Hospital上海市第十人民医院none32721611444123none0210205nonenonenone10nonenonenonenonenonenonenonenonenonenonenone27nonenonenone2none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tong Ren Hospital上海市同仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Xuhui Central Hospital上海徐汇中心医院nonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shibei Hospital上海市静安区市北医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shuguang Hospital上海中医药大学附属曙光医院nonenone20nonenonenonenonenonenonenonenone1none00nonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenone2nonenonenone3nonenonenonenonenonenonenonenone3nonenonenone11nonenonenonenonenonenonenonenonenone
Tongji Hospital同济大学附属同济医院none3none1730nonenone9nonenonenone212none21 open01 open0none185 opennonenonenonenonenonenonenonenonenonenonenone92nonenonenonenone2none0nonenonenonenone0none0nonenonenonenone0nonenonenonenonenonenonenonenonenone
Xinhua Hospital上海交通大学医学院附属新华医院nonenone21243212283215none401702nonenonenone7nonenonenonenonenonenonenone2none297363 open330nonenone0none10100001 open221 open1010364nonenonenonenonenonenone
Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangpu Hospital上海市杨浦区中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenone1nonenonenonenone
Zhabei Central Hospital上海市静安区闸北中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongshan Hospital, Fudan University复旦大学附属中山医院3568 open40816 open1348 open1864 open779 open441 open193none052802234 opennonenonenone142 open1nonenonenonenone0411 opennonenonenone10914 open30none0332 opennone313nonenonenone12none4nonenone10nonenonenone1none0nonenonenonenone
Zhongshan-Xuhui Hospital上海市徐汇区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Shanghai.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lung cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data